Lattice Biologics (TSXV:LBL.H) Change In Payables And Accrued Expense : C$1.83 Mil (TTM As of Jun. 2021)

View and export this data going back to 1995. Start your Free Trial

What is Lattice Biologics Change In Payables And Accrued Expense?

Lattice Biologics's Change In Payables And Accrued Expense for the quarter that ended in Jun. 2021 was C$0.00 Mil. It means Lattice Biologics's Accounts Payable & Accrued Expense stayed the same from Mar. 2021 to Jun. 2021 .

Lattice Biologics's Change In Payables And Accrued Expense for the fiscal year that ended in Sep. 2020 was C$1.98 Mil. It means Lattice Biologics's Accounts Payable & Accrued Expense increased by C$1.98 Mil from Sep. 2019 to Sep. 2020 .

Lattice Biologics Change In Payables And Accrued Expense Historical Data

The historical data trend for Lattice Biologics's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lattice Biologics Change In Payables And Accrued Expense Chart

Lattice Biologics Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Sep16

Sep17

Sep18

Sep19

Sep20

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

2.11

2.09

1.58

0.06

1.98

Lattice Biologics Quarterly Data
	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-	1.93	-0.10	-	-

Lattice Biologics Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Jun. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was C$1.83 Mil.

Lattice Biologics Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Lattice Biologics's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Lattice Biologics (TSXV:LBL.H) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lattice Biologics Ltd (TSXV:LBL.H) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

512 East Madison Avenue, Suite A1, Belgrade, MT, USA, 59714

Website

http://www.latticebiologics.com

Lattice Biologics Ltd is a biologic product manufacturing company. It manufactures and markets biologic products to domestic and international markets. The products of the company include ADM dermis, DBM Putty, Bone scaffold, and Others, of which key revenue is derived from Bone scaffold. The biologic products are used in various applications such as enhancing fusion in spine surgery, enhancing breast reconstruction post mastectomy for breast cancer patients, sports medicine applications, promotion of bone in foot and ankle surgery, promotion of skull healing following neurosurgery, and subchondral bone defect repair in knee and other joint surgeries. The company generates its revenue from operations principally carried in the United States of America.

Lattice Biologics (TSXV:LBL.H) Headlines

No Headlines